ArticleNaunyn-Schmiedeberg's archives of pharmacology2003
Somatostatin inhibits potassium-evoked glutamate release by activation of the sst(2) somatostatin receptor in the mouse retina.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Article
- Central somatostatin-somatostatin receptor 2 signaling mediates lactational suppression of luteinizing hormone release via the inhibition of glutamatergic interneurons during late lactation in rats.The Journal of reproduction and development · 2022Article
- Selective Interactions of Mouse Melanocortin Receptor Accessory Proteins with Somatostatin Receptors.Cells · 2022Article
- Molecular and Cellular Mechanisms Underlying Somatostatin-Based Signaling in Two Model Neural Networks, the Retina and the Hippocampus.International journal of molecular sciences · 2019Review
- Relationships Between Neurodegeneration and Vascular Damage in Diabetic Retinopathy.Frontiers in neuroscience · 2019Review
- Nanoparticle-Mediated Delivery of Neuroprotective Substances for the Treatment of Diabetic Retinopathy.Current neuropharmacology · 2018Review
- Article
- Neuroprotection as a Therapeutic Target for Diabetic Retinopathy.Journal of diabetes research · 2016Review
- Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives.Endocrine · 2014Review
- Somatostatin and its 2A receptor in dorsal root ganglia and dorsal horn of mouse and human: expression, trafficking and possible role in pain.Molecular pain · 2014Article
- The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story.Current neuropharmacology · 2013Article
- Vitreous levels of somatostatin in patients with chronic uveitic macular oedema.Eye (London, England) · 2012Article
- Protective role of somatostatin receptor 2 against retinal degeneration in response to hypoxia.Naunyn-Schmiedeberg's archives of pharmacology · 2012Article
- The somatostatinergic system in the mammalian cochlea.BMC neuroscience · 2011Article
- Adenylyl cyclase/cAMP system involvement in the antiangiogenic effect of somatostatin in the retina. Results from transgenic mice.Neurochemical research · 2008Article
- Somatostatin inhibits tooth-pulp-evoked rat cervical dorsal horn neuronal activity.Experimental brain research · 2008Article
- Somatostatin coupling to adenylyl cyclase activity in the mouse retina.Naunyn-Schmiedeberg's archives of pharmacology · 2004Article
- Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.Naunyn-Schmiedeberg's archives of pharmacology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the mammalian retina, somatostatin (SRIF-14) acts through distinct receptor subtypes (sst(1-5)). Among them, sst(2) has been localized to numerous retinal cells, including photoreceptors and rod bipolar cells (RBCs). The specific role of sst(2) in the retina is largely undetermined. In this study, we characterized retinas of mice with targeted deletion of sst(2) (sst(2) KO) and we investigated functions of sst(2) in respect to its possible modulation of glutamate (GLU) release, as measured by HPLC. In contrast with wild-type (WT) mice, sst(2) mRNA and sst(2A) immunoreactivity were no longer detectable in the retina of sst(2) KO mice. In retinal explants of WT mice, SRIF and its analogue octreotide that displays high selectivity for sst(2), similarly reduced the evoked release of GLU without affecting its basal level. In sst(2) KO retinas, SRIF or octreotide did not affect GLU release indicating that they act at sst(2). Unexpectedly, the compound CYN-154806, although introduced as the first potent sst(2) antagonist, reduced the evoked release of GLU with equipotency to SRIF and octreotide. Its inhibitory effect was no longer observed in sst(2) KO retinas, indicating that this substance acts at sst(2) receptors as an agonist. In conclusion, SRIF controls evoked release of GLU through sst(2) receptors and this control may represent part of a mechanism by which SRIF regulates GLU concentration in the retina.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.